In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction

Cellectis SA

www.cellectis.com

Latest From Cellectis SA

Bookmark
  • News

Servier To Tackle Parkinson's With Oncodesign Pact

By Kevin Grogan

A couple of years after Ipsen returned the rights to an LRRK2 Parkinson's program, Oncodesign has bagged a new partner in Servier and stands to bank up to €320m if all goes well.

Neurology Deals
Bookmark
  • Analysis

AstraZeneca, Novartis Continued Divestment Sprees In 2018, While Peers Joined The Action

By Joseph Haas and Janet Haniak

While leading large pharma with seven out-licensing or divestiture deals apiece during 2018, AstraZeneca and Novartis each slowed their pace somewhat. But several peer companies followed suit, as there were 31 such deals among the 20 largest biopharma firms last year.

 

Deals M & A
Bookmark
  • Analysis

CAR-T Forecast: Celgene Follows, But Also Leads As Next Batch Of T-Cell Therapies Near Market

By Mandy Jackson

Celgene's lead program will be the third autologous CD19-targeting T-cell therapy on the market, but the company is in the lead among BCMA-targeting CAR-T candidates. Next-generation technologies are also on the way.

ImmunoOncology Research and Development Strategies
Bookmark
  • Analysis

AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches

By Emily Hayes

This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.

Clinical Trials Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
        • Natural Products
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Cellectis SA
  • Senior Management
  • Andre Choulika, PhD, CEO
    Eric Dutang, CFO
    Elsy Boglioli, COO
    Philippe Duchateau, PhD, CSO
    Stephane Depil, MD, PhD, SVP, R&D & CMO
  • Contact Info
  • Cellectis SA
    Phone: (33) 81 69 16 00
    8 rue de la Croix Jarry
    Paris, 93235
    France
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By